SwanBio gets FDA Fast Track designation for adrenomyeloneuropathy therapy

Gene therapy company SwanBio Therapeutics has secured Fast Track designation from the US Food and Drug Administration (FDA) for its AAV-based gene therapy, SBT101, to treat adrenomyeloneuropathy (AMN) patients.